Insmed Growth Agent iPlex Joins Tercica’s Increlex With Orphan Exclusivity
Executive Summary
Insmed is focusing on the dosing schedule of its growth hormone treatment iPlex to distinguish it from Tercica's competing product Increlex
You may also be interested in...
Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18
The first half of 2006 could bring at least five novel oncologic approvals, including three for hematologic cancers
Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18
The first half of 2006 could bring at least five novel oncologic approvals, including three for hematologic cancers
Tercica Finishes First With Increlex Orphan Approval; Insmed Left In Dust?
FDA will decide a battle for orphan drug exclusivity in the extreme short stature market between Tercica's Increlex and Insmed's SomatoKine if and when Insmed's agent is approved, Tercica predicted